Short Interest in Itonic Holdings Ltd. (NASDAQ:ITOC) Drops By 59.0%

Itonic Holdings Ltd. (NASDAQ:ITOC) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 81,183 shares, a decline of 59.0% from the May 31st total of 197,966 shares. Based on an average trading volume of 3,686,350 shares, the short-interest ratio is presently 0.0 days. Approximately 0.5% of the shares of the company are sold short.

Itonic Price Performance

Shares of Itonic stock traded down $0.00 during trading on Monday, reaching $0.30. The company’s stock had a trading volume of 73,794 shares, compared to its average volume of 2,740,487. The stock has a 50-day moving average price of $0.33. Itonic has a fifty-two week low of $0.25 and a fifty-two week high of $32.00.

Itonic (NASDAQ:ITOC) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Itonic from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 5th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

About Itonic

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.